SPECTRAL MEDICAL INC (EDT.CA) Stock Price, Forecast & Analysis
TSX:EDT • CA8475771033
EDT.CA Key Statistics, Chart & Performance
The current stock price of EDT.CA is 1.37 CAD. In the past month the price increased by 3.79%. In the past year, price increased by 110.77%.
EDT.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EDT.CA. When comparing the yearly performance of all stocks, EDT.CA is one of the better performing stocks in the market, outperforming 78.9% of all stocks.
EDT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EDT.CA. EDT.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
EDT.CA Financial Highlights
Over the last trailing twelve months EDT.CA reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS decreased by -62.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -513.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EDT.CA Forecast & Estimates
6 analysts have analysed EDT.CA and the average price target is 3.16 CAD. This implies a price increase of 130.8% is expected in the next year compared to the current price of 1.37.
For the next year, analysts expect an EPS growth of -100% and a revenue growth -14.99% for EDT.CA
EDT.CA Ownership
EDT.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 580.689M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 152.76M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 71.733M | ||
| COV | COVALON TECHNOLOGIES LTD | 12.94 | 44.192M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 40.89M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 28.756M | ||
| HEM | HEMOSTEMIX INC | N/A | 16.596M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About EDT.CA
Company Profile
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.
Company Info
SPECTRAL MEDICAL INC
135 The West Mall, Unit 2
TORONTO ONTARIO M9C 1C2 CA
CEO: Chris Seto
Employees: 29
Phone: 14166263233
SPECTRAL MEDICAL INC / EDT.CA FAQ
What does SPECTRAL MEDICAL INC do?
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.
What is the current price of EDT stock?
The current stock price of EDT.CA is 1.37 CAD. The price increased by 6.2% in the last trading session.
Does EDT stock pay dividends?
EDT.CA does not pay a dividend.
How is the ChartMill rating for SPECTRAL MEDICAL INC?
EDT.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting EDT stock to perform?
6 analysts have analysed EDT.CA and the average price target is 3.16 CAD. This implies a price increase of 130.8% is expected in the next year compared to the current price of 1.37.
How many employees does SPECTRAL MEDICAL INC have?
SPECTRAL MEDICAL INC (EDT.CA) currently has 29 employees.
Can you provide the market cap for SPECTRAL MEDICAL INC?
SPECTRAL MEDICAL INC (EDT.CA) has a market capitalization of 400.81M CAD. This makes EDT.CA a Small Cap stock.